Emulate’s Organ-on-Chip Technology in the 2nd Inning, Still Has Room to Grow

Boston, MA-based Emulate has raised $82 million in a series E round to further develop its organ-on-chip technology. Late last year, the company signed partnerships with FDA and the U.S. Army to use its technology to evaluate the impact of COVID-19 and vaccines for the virus.